We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Amalgamated Financial
AMAL
$1.45B
| $7.04M | 0.03% |
437,593
+44,205
| +11% | +$710K |
|
177
Gilead Sciences
GILD
$162B
| $6.84M | 0.03% |
88,779
-7,147
| -7% | -$570K |
|
178
Vanguard Small-Cap ETF
VB
$79.3B
| $6.78M | 0.02% |
34,079
-3,168
| -9% | -$599K |
|
179
Gen Digital
GEN
$15.1B
| $6.74M | 0.02% |
363,339
-1,300
| -0.4% | -$22.7K |
|
180
Chevron
CVX
$387B
| $6.72M | 0.02% |
42,722
-7,321
| -15% | -$1.17M |
|
181
Pliant Therapeutics
PLRX
$66.9M
| $6.71M | 0.02% |
370,200
| – | – |
|
182
Newmont
NEM
$101B
| $6.65M | 0.02% |
155,800
-145
| -0.1% | -$6.58K |
|
183
Liberty Broadband Class A
LBRDA
$4.26B
| $6.41M | 0.02% |
85,266
-4,111
| -5% | -$317K |
|
184
General Mills
GIS
$19B
| $6.39M | 0.02% |
83,269
-2,387
| -3% | -$204K |
|
185
Texas Instruments
TXN
$260B
| $6.38M | 0.02% |
35,427
-2,319
| -6% | -$399K |
|
186
BioCryst Pharmaceuticals
BCRX
$2.38B
| $6.16M | 0.02% |
874,840
| – | – |
|
187
Nasdaq
NDAQ
$51.1B
| $6.15M | 0.02% |
123,369
-954
| -0.8% | -$51.7K |
|
188
Becton Dickinson
BDX
$42.1B
| $6.11M | 0.02% |
23,157
-3,697
| -14% | -$939K |
|
189
Crown Castle
CCI
$32.6B
| $6.09M | 0.02% |
53,472
-12,520
| -19% | -$1.49M |
|
190
Brookfield Infrastructure
BIPC
$5.12B
| $6.07M | 0.02% |
133,167
-1,437
| -1% | -$65.3K |
|
191
Analog Devices
ADI
$185B
| $6M | 0.02% |
30,773
-2,833
| -8% | -$525K |
|
|
UBA
192
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $5.97M | 0.02% |
280,660
-14,750
| -5% | -$275K |
|
193
Illinois Tool Works
ITW
$79.7B
| $5.84M | 0.02% |
23,339
-2,540
| -10% | -$595K |
|
194
Ameren
AEE
$31.3B
| $5.77M | 0.02% |
70,627
-1,840
| -3% | -$158K |
|
|
QIPT
195
DELISTED
Quipt Home Medical
QIPT
| $5.74M | 0.02% |
1,075,000
+73,750
| +7% | +$435K |
|
196
Boston Properties
BXP
$10.8B
| $5.7M | 0.02% |
98,916
+5,849
| +6% | +$304K |
|
197
Vanguard Small-Cap Value ETF
VBR
$36.8B
| $5.67M | 0.02% |
34,270
-2,521
| -7% | -$397K |
|
198
Artesian Resources
ARTNA
$350M
| $5.65M | 0.02% |
119,591
-6,485
| -5% | -$341K |
|
199
Avis
CAR
$5.62B
| $5.59M | 0.02% |
24,455
+50
| +0.2% | +$9.16K |
|
200
Lennar Class B
LEN.B
$19.4B
| $5.54M | 0.02% |
51,603
-5,875
| -10% | -$551K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.